Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs

Journal of Clinical Virology

Volumn 58, Issue 4, 2013, Pages 713-717

  Ouzan, Denis ^a   Pénaranda, Guillaume ^b   Joly, Hélène ^a   Khiri, Hacène ^b   Pironti, Antonnella ^a   Halfon, Philippe ^b,c  

^a INSTITUT ARNAULT TZANCK   (France)

^b Laboratoire Alphabio   (France)

^c Unité de médecine interne Hôpital européen   (France)

Author keywords

Add on Peg interferon; HBeAg; HBsAg

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; INTERLEUKIN 28B; LAMIVUDINE; NUCLEOTIDE DERIVATIVE; PEGINTERFERON ALPHA2A; TENOFOVIR; VIRUS DNA;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DNA POLYMORPHISM; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIMIT OF DETECTION; LONG TERM CARE; MALE; MONOTHERAPY; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROCONVERSION; TREATMENT DURATION;

ADD-ON PEG-INTERFERON; BASELINE; BL; CHB; CHRONIC HEPATITIS B; HBEAG; HBSAG; NA; NUCLEOTIDE ANALOGS; PEG-IFN; PEGYLATED INTERFERON-ALPHA; W120; W48; W96; WEEK 120; WEEK 48; WEEK 96;

ADENINE; ADULT; AGED; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS;

EID: 84888839700     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2013.09.020     Document Type: Article

References (23)

1. Funk M.L., Rosenberg D.M., Lok A.S. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 2002, 9(1):52-61.
2. Liaw Y.F., Brunetto M.R., Hadziyannis S. The natural history of chronic HBV infection and geographical differences. Antivir Ther 2010, 15(Suppl. 3):25-33.
3. EASL EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009, 50:227-242.
4. EASL EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2012, 57:167-185.
5. Shouval D., Lai C.L., Chang T.T., Cheinquer H., Martin P., Carosi G., et al. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol 2009, 50(2):289-295.
6. Liang Y., Jiang J., Su M., Liu Z., Guo W., Huang X., et al. Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. Aliment Pharmacol Ther 2011, 34(3):344-352.
7. Liu F., Wang L., Li X.Y., Liu Y.D., Wang J.B., Zhang Z.H., et al. Poor durability of lamivudine effectiveness despite stringent cessation criteria: a prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients. J Gastroenterol Hepatol 2011, 26(3):456-460.
8. Wedemeyer H., Yurdaydin C., Dalekos G.N., Erhardt A., Cakaloglu Y., Degertekin H., et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011, 364(4):322-331.
9. Marcellin P., Avila C., Wursthorn K., Chuang W.-L., Lau G., Peng C.-Y. Telbivudine plus peg-interferon in HBeAg-positive chronic hepatitis B - very potent antiviral efficacy but risk of peripheral neuropathy. J Hepatol 2012, 52(s1):s6-s7.
10. Boglione L., D'Avolio A., Cariti G., Milia M.G., Simiele M., De Nicolo A., et al. Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes. J Viral Hepat 2013, 20(4):e11-e19.
11. Jaroszewicz J., Ho H., Markova A., Deterding K., Wursthorn K., Schulz S., et al. B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues. Antivir Ther 2011, 16(6):915-924.
12. Kittner J.M., Sprinzl M.F., Grambihler A., Weinmann A., Schattenberg J.M., Galle P.R., et al. Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B. J Clin Virol 2012, 54(1):93-95.
13. Halfon P., Ouzan D., Khiri H., Penaranda G., Castellani P., Oules V., et al. Detection of IL28B SNP DNA from buccal epithelial cells, small amounts of serum, and dried blood spots. PLoS ONE 2012, 7(3):e33000.
14. Lampertico P., Vigano M., Di Costanzo G.G., Sagnelli E., Fasano M., Di Marco V., et al. Randomised study comparing 48 and 96 weeks peginterferon alpha-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut 2012, 62(2):290-298.
15. Invernizzi F., Lampertico P., Loglio A., Iavarone M., Vigano M., Facchetti F., et al. Nucleos(t)ide analogues can be safely discontinued in CHB patients achieving HBsAg clearance. Hepatology 2012, 56(s1):368A.
16. Lampertico P., Soffredini R., Vigano M., Minola E., Cologni G., Rizzi M., et al. Entecavir treatment for NUC naïve, field practice patients with chronic hepatitis B: excellent viral suppression and safety profile over 5 years of treatment. Hepatology 2012, 56(s1):370A.
17. Hadziyannis S.J., Tassopoulos N.C., Heathcote E.J., Chang T.T., Kitis G., Rizzetto M., et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005, 352(26):2673-2681.
18. Marcellin P., Bonino F., Lau G.K., Farci P., Yurdaydin C., Piratvisuth T., et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009, 136(7). [2169-79 e1-4].
19. Fasano M., Lampertico P., Marzano A., Di Marco V., Niro G.A., Brancaccio G., et al. HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years. J Hepatol 2012, 56(6):1254-1258.
20. Petersen J., Buggish P., Stoehr A., Hinrichsen H., Pouss S., Berg T. Stopping long term nucleo(t)ide analogue therapy before HBsAg loss in HBe negative CHB patients: experience of five referal centers in Germany. J Hepatol 2012, 54(s1):s299-s300.
21. Lampertico P., Invernizzi F., Facchetti F., Soffredini R., Lungh G., Vigano M. Add-on PEG-IFN improves HBsAg kinetics in patients long-term fully suppressed by nucleos(t)ide analogs. J Hepatol 2012, 56(s2):s207.
22. Sonneveld M.J., Xie Q., Zhang N., Zhang Q., Tabok F., Streinu-Cercel A. Adding peginterferon alpha-2a to entecavir increases HBsAg decline and HBeAg clearance-first results from a global randomized trial (ARES Study). Hepatology 2012, 56(s1):199A.
23. Ouzan D., Penaranda G., Joly H., Halfon P. Optimized HBsAg titer monitoring improves interferon therapy in patients with chronic hepatitis delta. J Hepatol 2013, 58(6):1258-1259.